Predictive Technology Group (Predictive Technology Group) Buyback Yield % : 0.00 (As of May. 21, 2024)

View and export this data going back to 2007. Start your Free Trial

What is Predictive Technology Group Buyback Yield %?

Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.

Predictive Technology Group's current buyback yield was 0.00%.

Predictive Technology Group Buyback Yield % Historical Data

The historical data trend for Predictive Technology Group's Buyback Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Predictive Technology Group Buyback Yield % Chart

Predictive Technology Group Annual Data

Trend

Aug06

Aug07

Jun16

Jun17

Jun18

Jun19

Jun20

Buyback Yield %

Get a 7-Day Free Trial

-0.30

-0.65

-0.38

Predictive Technology Group Quarterly Data
	Nov07	Feb08	May08	Jun16	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21
Buyback Yield %	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Predictive Technology Group's Buyback Yield %

For the Biotechnology subindustry, Predictive Technology Group's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Predictive Technology Group's Buyback Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Predictive Technology Group's Buyback Yield % distribution charts can be found below:

* The bar in red indicates where Predictive Technology Group's Buyback Yield % falls into.

Predictive Technology Group Buyback Yield % Calculation

Buyback yield is a measure of shareholder return.

Predictive Technology Group's Buyback Yield for the fiscal year that ended in Jun. 2020 is calculated as

Buyback Yield	=	Net Issuance of Stock			/	Market Cap
	=	- (Repurchase of Stock	+	Issuance of Stock)	/	Market Cap
	=	- (0	+	0.48)	/	125.83074
	=	-0.38%

Predictive Technology Group's annualized Buyback Yield for the quarter that ended in Mar. 2021 is calculated as

Buyback Yield	=	Net Issuance of Stock		(Annualized)			/	Market Cap
	=	- (Repurchase of Stock	+	Issuance of Stock)	*	Annualized Factor	/	Market Cap
	=	- (0	+	0)	*	4	/	47.93552
	=	0.00%

In calculating the annualized quarterly data, the Repurchase of Stock and Issuance of Stock data used here is four times the quarterly (Mar. 2021) data.

Predictive Technology Group Buyback Yield % Related Terms

Thank you for viewing the detailed overview of Predictive Technology Group's Buyback Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.

Predictive Technology Group (Predictive Technology Group) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Predictive Technology Group Inc (OTCPK:PRED) » Definitions » Buyback Yield %

Comparable Companies

Traded in Other Exchanges

N/A

Address

2735 Parleys Way, Suite 205, Salt Lake City, UT, USA, 84109

Website

https://www.predtechgroup.com

Predictive Technology Group Inc (PRx) is a biotechnology company. It develops, commercializes, acquires and invests in technologies engaged in novel molecular diagnostic and therapeutic products in healthcare. The HCT/P segment offers minimally manipulated tissue products intended for homologous use, prepared utilizing proprietary extraction methods that reduce the loss of important scaffolding, growth factors and cytokines. The company's Diagnostics and Therapeutics segment uses data analytics for disease identification and subsequent therapeutic intervention through novel gene-based diagnostics, and companion therapeutics. It generates most of its revenues from HCT/Ps segment.